RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Phase of Trial: Phase II/III
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Irinotecan (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms RESILIENT
- Sponsors Ipsen
- 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer.
- 07 Sep 2018 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 07 Sep 2018 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2022.